Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules
CAMN107AIT15
Phase 2 small_molecule active
Quick answer
Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules for Chronic myeloid leukemia is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Chronic myeloid leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active